McClung MR - Search Results

1

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P. McClung MR, et al. Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0. Epub 2012 Jun 30. Osteoporos Int. 2013. PMID: 22752050 Free PMC article. Clinical Trial.

2

Quality control of DXA instruments in multicenter trials.

Faulkner KG, McClung MR. Faulkner KG, et al. Among authors: mcclung mr. Osteoporos Int. 1995;5(4):218-27. doi: 10.1007/BF01774010. Osteoporos Int. 1995. PMID: 7492859

3

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al. Chesnut CH 3rd, et al. Among authors: mcclung mr. Am J Med. 1995 Aug;99(2):144-52. doi: 10.1016/s0002-9343(99)80134-x. Am J Med. 1995. PMID: 7625419 Clinical Trial.

4

Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites.

Faulkner KG, McClung MR, Coleman LJ, Kingston-Sandahl E. Faulkner KG, et al. Among authors: mcclung mr. Osteoporos Int. 1994 Jan;4(1):42-7. doi: 10.1007/BF02352260. Osteoporos Int. 1994. PMID: 8148571

5

Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.

McClung MR. McClung MR. Bone. 1996 Nov;19(5 Suppl):195S-198S. doi: 10.1016/s8756-3282(96)90165-9. Bone. 1996. PMID: 8922662 Review.

6

Discrepancies in normative data between Lunar and Hologic DXA systems.

Faulkner KG, Roberts LA, McClung MR. Faulkner KG, et al. Among authors: mcclung mr. Osteoporos Int. 1996;6(6):432-6. doi: 10.1007/BF01629574. Osteoporos Int. 1996. PMID: 9116387

7

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. McClung M, et al. Ann Intern Med. 1998 Feb 15;128(4):253-61. doi: 10.7326/0003-4819-128-4-199802150-00001. Ann Intern Med. 1998. PMID: 9471927 Clinical Trial.

8

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ. Siris ES, et al. Among authors: mcclung mr. J Bone Miner Res. 1998 Jun;13(6):1032-8. doi: 10.1359/jbmr.1998.13.6.1032. J Bone Miner Res. 1998. PMID: 9626635 Free article. Clinical Trial.

9

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Meunier PJ, et al. Among authors: mcclung mr. Clin Ther. 1999 Jun;21(6):1025-44. doi: 10.1016/s0149-2918(99)80022-8. Clin Ther. 1999. PMID: 10440625 Review.

10

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ. Schnitzer T, et al. Aging (Milano). 2000 Feb;12(1):1-12. Aging (Milano). 2000. PMID: 10746426 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page